We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Backs MDUFA IV, Will Watch for Results
Industry representatives have endorsed measures that would streamline the FDA’s premarket review process, but said they will be watching closely for tangible results in exchange for a $320 million increase in user fees.